A pelvic patient is receiving a weekly radiosensitizing chemotherapy drug during external beam treatment, has daily CBCT image guidance, and a brachytherapy boost is planned once the beam course ends. Before that boost is scheduled, which dose contribution should you flag for the physicist so tissue tolerance for bowel and skin is assessed correctly?
Select an answer to reveal the explanation.
Short Explanation
Flag the cumulative dose to bowel and skin from both external beam treatment and brachytherapy so your physicist can assess tissue tolerance accurately. Chemotherapy can raise toxicity risk, but it isn’t another dose to add—like a modifier, not another ingredient in the dose tally.
Full Explanation
For a tolerance review, assess the cumulative therapeutic dose to the relevant normal tissues from external beam treatment and brachytherapy. Record concurrent chemotherapy and consider its effect on toxicity risk, but do not treat it as a physical dose that can be added to the dose total. Imaging exposure is also distinct from therapeutic dose; CBCT dose should not be routinely added to the treatment dose total without a specific departmental or clinical reason. Checking only the current contour dose omits the planned boost, while documenting chemotherapy alone does not assess cumulative tissue dose. Confirm with the physicist how the department evaluates these contributions and any relevant clinical modifiers.